TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02998099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: A single dose of IV rivipansel over 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: A single dose of IV rivipansel over 20 minutes.
Study: NCT05714228

Intervention type: PROCEDURE
Intervention: Surgical Mitral Valve Repair
Description: Mitral valve is repaired using open surgical approach

Intervention type: PROCEDURE
Intervention: Transcatheter Mitral Valve Repair
Description: Mitral valve is repaired using Mitraclip transcatheter device
Study: NCT00510562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial osteopathic manipulation
Description: This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham/Placebo
Description: A laying on of hands with no treatment being performed.
Study: NCT03148782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OST Intervention for participants with Organizational skill difficulties
Description: Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
Study: NCT01197105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Use of natural product (Schinus terebinthifolius)
Description: Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
Study: NCT03915600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quinoa and Flaxseed
Description: personalized diet added with quinoa and flaxseed
Study: NCT02719665

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SPM Emulsion, Dose-modality
Description: Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SPM Softgel, Dose-Modality
Description: Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Softgel
Description: Days 43-47: 4 Placebo softgel; Day 48-64 Washout
Study: NCT01724463

Intervention type: OTHER
Intervention: Severe Sepsis Management Bundle
Description: Management Bundle includes:~1. Securing Intravenous Access~2. Obtaining Blood Culture~3. Antibiotic Administration~4. Goal Directed Fluid Bolus Therapy~5. Oxygen Administration~6. Measuring Serum Lactate Levels
Study: NCT03045458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tissue level dental implant
Description: After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone level dental implant
Description: After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
Study: NCT02959879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX neoadjuvant chemotherapy
Description: 4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX neoadjuvant chemotherapy
Description: 4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative surgery for resectable pancreatic duct adenocarcinoma
Description: curative surgery for resectable pancreatic duct adenocarcinoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative surgery for resectable pancreatic duct adenocarcinoma
Description: curative surgery for resectable pancreatic duct adenocarcinoma
Study: NCT01060345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
Study: NCT02712814

Intervention type: DRUG
Intervention: Topical hormonal cream (estrogen)
Description: Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months

Intervention type: DRUG
Intervention: Topical hormonal cream (estrogen)
Description: Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months

Intervention type: PROCEDURE
Intervention: Pelvic floor physical therapy
Description: PF physical therapy once weekly for 3 months

Intervention type: PROCEDURE
Intervention: Pelvic floor physical therapy
Description: PF physical therapy once weekly for 3 months

Intervention type: PROCEDURE
Intervention: Pelvic floor physical therapy
Description: PF physical therapy once weekly for 3 months

Intervention type: PROCEDURE
Intervention: Low Level Laser therapy
Description: non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule

Intervention type: PROCEDURE
Intervention: Low Level Laser therapy
Description: non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule

Intervention type: PROCEDURE
Intervention: Low Level Laser therapy
Description: non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
Study: NCT03597217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: 3, 10, 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: 50 mg multiple dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04016740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intraoperative infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Intraoperative infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intraoperative infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Intraoperative intermittent bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intraoperative infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Intraoperative inhaled as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Post-operative infusion
Study: NCT02728726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
Study: NCT04909411

Intervention type: OTHER
Group type: OTHER
Intervention: OPHTHALMOLOGICAL ASSESSMENT
Description: assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination

Intervention type: OTHER
Group type: OTHER
Intervention: OPHTHALMOLOGICAL ASSESSMENT
Description: assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination

Intervention type: OTHER
Group type: OTHER
Intervention: NEUROPSYCHOLOGICAL ASSESSMENT
Description: completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: NEUROPSYCHOLOGICAL ASSESSMENT
Description: completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire
Study: NCT03556280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaSense Stimulation System (Active Settings)
Description: Proprietary auditory and visual sensory stimulation device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GammaSense Stimulation System (Sham Settings)
Description: Proprietary auditory and visual sensory stimulation device.
Study: NCT03380988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute test meal with fiber-enriched buckwheat pasta
Description: Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute test meal with corn pasta
Description: Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
Study: NCT02559960

Intervention type: DRUG
Intervention: Breviscapine Powder-Injection
Description: Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Study: NCT04189588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine HCl 10 mg/mL
Description: Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine 50 mg/mL
Description: Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
Study: NCT01807078

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceuticals
Description: 1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
Study: NCT04189588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-CD20 such as Rituximab or Paclitaxel
Description: Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-CD20 such as Rituximab or Paclitaxel
Description: Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
Study: NCT03944005

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia + ACB continious catheter + iPACK + Sham LIA
Description: ACB - On identification of adductor canal,10ml ropivacaine 0.5% with 1:400,000 epinephrine will be injected to surround the femoral artery.Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr 0.2% ropivacaine will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of femoral condyle and popliteal artery, 20ml ropivacaine 0.5% with 1:400,000 epinephrine will be infiltrated in muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients in Group 1 will receive local infiltration 100ml of normal saline around the knee capsule of 100ml of normal saline by the surgeons as a Sham injection.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Spinal Anesthesia + LIA + Sham Blocks
Description: ACB - On identification of adductor canal, 10ml of saline as a sham solution will be injected to surround the femoral artery. Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr of saline will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of the femoral condyle and popliteal artery, 20ml of saline will be infiltrated in the muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following the nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine injected at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients will receive local infiltration by the attending surgeon intraoperatively with 300mg of ropivacaine (100ml of 0.3% ropivacaine),30 mg of ketorolac, and 10mg of morphine around the knee capsule.
Study: NCT03592992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal Hydromorphone
Description: 75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Morphine
Description: 150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
Study: NCT01795339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study: NCT01496859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement and use of Baska mask
Description: use of a supraglottic airway device as a standard part of a general anaesthetic
Study: NCT03932383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom CPAP mask
Description: Modified CPAP mask based on 3D image capture
Study: NCT00271570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade)
Description: Remicade was 5 mg/kg IV (single dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Description: 2nd dose of IVIG (2g/kg)
Study: NCT03529422

Intervention type: DRUG
Group type: OTHER
Intervention: Durvalumab
Description: Durvalumab 1500mg IV every 3 weeks for 6 cycles

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity Modulated Radiotherapy Treatments
Description: Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
Study: NCT01103986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational/health literacy education (Test group)
Description: Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick.
Study: NCT03627988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with invasive breast cancer will receive:
Description: * Mastectomy with Immediate prosthetic breast reconstruction~* Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy).
Study: NCT02522975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPIAO®
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPREX®
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study: NCT05788354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUD insertion during cesarean section
Description: placement of IUD during cesarean section after placental delivery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUD insertion during cesarean section
Description: placement of IUD during cesarean section after placental delivery
Study: NCT01081938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine
Study: NCT00097370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepolizumab
Description: Study Drug
Study: NCT02610257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical stimulus (vibration) applied on the forearm
Description: Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical stimulus (vibration) applied on the forearm
Description: Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical stimulus (vibration) applied on the forearm
Description: Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical stimulus (vibration) applied on the forearm
Description: Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports.
Study: NCT00799864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged \>=12 to \<18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged \>=6 to \<12 years) or 25 mg once daily for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).